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a b s t r a c t
MicroRNA miR-146a and PLZF are reported as major players in the control of hematopoiesis, immune
function and cancer. PLZF is described as a miR-146a repressor, whereas CXCR4 and TRAF6 were
identiﬁed as miR-146a direct targets in different cell types. CXCR4 is a co-receptor of CD4 molecule that
facilitates HIV-1 entry into T lymphocytes and myeloid cells, whereas TRAF6 is involved in immune
response. Thus, the role of miR-146a in HIV-1 infection is currently being thoroughly investigated.
In this study, we found that PLZF mediates suppression of miR-146a to control increases of CXCR4
and TRAF6 protein levels in human primary CD4þ T lymphocytes. We show that miR-146a upregulation
by AMD3100 treatment or PLZF silencing, decreases CXCR4 protein expression and prevents HIV-1
infection of leukemic monocytic cell line and CD4þ T lymphocytes.
Our ﬁndings improve the prospects of developing new therapeutic strategies to prevent HIV-1 entry
via CXCR4 by using the PLZF/miR-146a axis.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The ability of human immunodeﬁciency virus type 1 (HIV-1) to
bind to and enter into CD4þ T cells depends on optimal expression
of CD4þ protein on the surface of these cells (Wilen et al., 2012).
However, chemokine receptors, in particular CCR5 and CXCR4, are
essential coreceptors of CD4þ molecules on cell membrane of T
lymphocytes and other cell types, such as monocytes/macrophages
and dendritic cells, to allow HIV-1 entry into these cells (Wilen et
al., 2012). Thus, receptor-coreceptors which determine viral entry
into various cell types, together with the cellular tropism which
deﬁnes viral phenotype, are among the major factors inﬂuencing
HIV pathogenesis (Wu and Yoder, 2009; Naif, 2013).
At the present, the current classiﬁcation of cellular tropism of
HIV-1 relies on the differential expression of CCR5 and CXCR4 in
monocytes/macrophages and T-cell lines (Wilen et al., 2012; Naif,
2013). Monocytes/macrophages serve as vehicles for viral disse-
mination between different tissues of the body (Ryan et al., 2002;
Ciborowski and Gendelman, 2006; Carter et al., 2010, 2011), thus
acting as reservoirs for HIV-1 in tissues (Van Lint et al., 2013).
Then, CCR5 and CXCR4 are relevant targets for pharmaceutical
intervention that aims to block HIV-1 entry into macrophages and
primary T lymphocytes and to prevent viral dissemination (Proudfoot,
2002; Henrich and Kuritzkes, 2013).
Coreceptor binding of their natural ligands, such as RANTES/CCL5,
MIP-1alpha/CCL3, and MIP-1beta/CCL4 for CCR5 and stromal-derived
factor, SDF-1/CXCL12, for CXCR4, inhibits HIV-1 entry into CD4þ T
cells, monocytic and CD4þ T cell lines (Naif, 2013). However, any
change in co-receptors conformation and surface density on cell
membrane impacts the overall susceptibility of a given cell type for
HIV infection (Lapham et al., 2002; Sloane et al., 2005; Richardson
et al., 2012) and may alter the effectiveness of small drugs targeting
HIV co-receptors (Proudfoot, 2002; Choi et al., 2012a, 2012b). Then,
the discovery of HIV-1 cellular entry inhibitors remains an important
objective in molecular pharmacology.
The ﬁrst clinical trials with the highly speciﬁc CXCR4 antagonist,
AMD3100 (Mozobil, plerixafor), were designed for treatment of HIV
(Hendrix et al., 2000). Approved by Food and Drug Administration
(FDA) as a mobilizer of hematopoietic CD34þ cells from the bone
marrow to the circulation (Hendrix et al., 2000; DiPersio et al.,
2009), AMD3100 is also used to inhibit growth and metastasis
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of experimental tumors in animal models, as CXCR4 is also involved
in metastatic dissemination, growth and survival of cancer cells,
including leukemic cells (Domanska et al., 2013).
However AMD3100 is not being further developed for antiretro-
viral therapy (Hendrix et al., 2004). Highly active antiretroviral therapy
(HAART) is currently the only option to control the progression of
HIV-1 infection, improve the quality of life of HIV patients and reduce
morbidity. Unfortunately, HAART that restores immunological function
and helps prevent further diseases transmission, has also developed
the phenomenon of drug resistance, a critical factor responsible for
failure of this combined therapy (Deeks et al., 2012). In this context,
the search for new anti-HIV drugs has been extended to compounds
that act against cellular rather than viral target to minimize viral
mutagenesis that give rise for drug resistance.
More recently, manipulation of microRNAs (miRNAs) has been
proposed as a novel approach to use against HIV-1 infection and for
purging the HIV-1 reservoir (Van Lint et al., 2013; Tyagi and
Bukrinsky, 2012). miRNAs are small non-coding RNA involved in
posttranscriptional gene regulation that participates in RNA inter-
ference (RNAi)-mediated gene silencing (Bartel, 2009). RNAi activity
is involved in many eukaryotic cellular processes and the deregu-
lated expression of miRNAs and other RNAi components has been
described in cancers, metabolic disorders, and infectious diseases
(Triboulet et al., 2007; Bivalkar-Mehla et al., 2011; Yeung and Jeang,
2011; Klase et al., 2012). These miRNAs represent a new generation
biomarkers for diagnostics and prognostics and, given their stability
in vivo (Yeung and Jeang, 2011), new tools to control speciﬁc target
in disease, including AIDS (Klase et al., 2012).
The role of viral-encoded miRNAs derived from viral genomes
(Pfeffer et al., 2004) in virus replication and virus-host interaction
is currently under investigation (Ouellet et al., 2013; Zhang et al.,
2014), as well as the role of cellular miRNAs in the regulation of
HIV-1 viral replication (Lecellier et al., 2005; Huang et al., 2007)
and in the complex interactions with HIV-1 (Klase et al., 2012).
miRNA 146a (miR-146a) is considered as a crucial modulator of
differentiation and function of cells of the innate and adaptive
immunity, acting as a negative feedback regulator of the innate
immune response by targeting two adapter proteins, TRAF6 (Tumor
necrosis factor receptor -associated factor 6) and IRAK1(IL-1 receptor-
associated kinase 1), acting in pro-inﬂammatory signaling (Taganov
et al., 2006; Hou et al., 2009). The latent membrane protein 1 (LMP1),
a major oncoprotein of the Epstein-Barr virus (EBV), induces cellular
miR-146a expression that may contribute to cellular immortalization
and tumorigenesis (Cameron et al., 2008). miR-146a also promotes
vesicular stomatitis virus (VSV) replication in macrophages (Hou et al.,
2009). The chemokine CCL8/MCP-2, ligand for CCR5 but also potent
inhibitor of CD4/CCR5-mediated HIV-1 entry and replication, is also a
target of miR-146a in HIV-1 infected microglia (Rom et al., 2010).
Beside its role in immune responses and in disease (Taganov
et al., 2006; Boldin et al., 2011; Burger et al., 2014), miR-146a has
been also involved in the control of hematopoiesis (Labbaye et al.,
2008; Labbaye and Testa, 2012).
We have demonstrated that CXCR4 is a direct target of miR-146a
in hematopoietic normal and leukemic cells and identiﬁed the
transcription factor PLZF (promyelocytic leukemia zinc ﬁnger) as a
repressor of miR-146a expression in megakaryocytic (Mk) cells
(Labbaye et al., 2008).
PLZF was initially identiﬁed as a protein whose functions are
subverted through chromosomal rearrangements resulting in acute
promyelocytic leukemia (Suliman et al., 2012). It is known to regulate
progenitor maintenance in multiple tissues (Kelly and Daniel, 2006).
Subsequently, PLZF has been found to be a key stem cell maintenance
factor in both the hematopoietic system and male germline (Suliman
et al., 2012). PLZF was also shown to be a critical regulator of immune
system development and function, also implicated in carcinogenesis
as a tumor suppressor gene (Suliman et al., 2012). More recently, we
have described the regulation of CXCR4 by miR-146a targeting in
monocytic (Mo) cells and showed that the enforced expression of
miR-146a by AMD3100 treatment, decreases total CXCR4 protein
expression and impairs Mo leukemic cell proliferation (Spinello et al.,
2011).
In the present study, we showed that PLZF, miR-146a and
CXCR4 are expressed and regulated during activation of human
primary CD4þ T lymphocytes. TRAF6 expression and regulation
was also analyzed in the same cells, as another target gene of miR-
146a. In addition, we studied the effects of AMD3100 treatment on
miR-146a and CXCR4 expression levels in CD4þ T lymphocytes
and during HIV-1 infection of these cells.
We found that PLZF mediates suppression of miR-146a to control
increases of CXCR4 and TRAF6 expression levels in CD4þ T
lymphocytes, whereas miR-146a upregulation by AMD3100 treat-
ment or PLZF silencing, decreases CXCR4 protein expression level
and inhibits HIV-1 infection of CD4þ T lymphocytes.
Altogether, we showed that the PLZF/miR-146a axis that con-
trols CXCR4 expression in CD4þ T lymphocytes, can be used to
prevent HIV-1 entry into CD4/CXCR4 expressing target cells in new
therapeutic strategies against HIV-1 infection.
Results
PLZF, miR-146a, CXCR4 and TRAF6 expression and regulation in
human primary CD4þ T lymphocytes
We previously described in human Mk cells that PLZF sup-
presses miR-146a transcription and thereby activates CXCR4 trans-
lation (Labbaye et al., 2008). To investigate whether this cascade
pathway may be present and functional in human primary CD4þ T
lymphocytes, we ﬁrst analyzed PLZF and miR-146a expression and
regulation in CD4þ T lymphocytes puriﬁed from human peripheral
blood (PB), activated by PHA treatment and maintained in culture
for few days, as compared to resting CD4þ T lymphocytes (day 0).
Then, we examined CXCR4 and TRAF6 expression in the same cells.
Western blot analysis showed that PLZF protein expression,
undetectable in resting cells, increases during PHA-activation of
CD4þ T lymphocytes (Fig. 1A), whereas miR-146a expression,
analyzed by real time PCR, decreases in the same cells (Fig. 1B).
By using real time PCR analysis, we found that CXCR4 mRNA,
expressed at very high level in non activated CD4þ T lymphocytes
(day 0, Fig. 1C), rapidly decreases during the ﬁrst hours of activation
(0 to 6 hours of culture, Fig. 1C), then remains at a lower but
constant level in activated CD4þ T cells (16 to 48 hours of culture,
Fig. 1C), in a range of expression quite similar to CXCR4 mRNA levels
found in Jurkat and U937 cells (Fig. 1C).
Western blot analysis performed as compared to Jurkat cells, a
positive control expressing the 45 kDa isoform of CXCR4 protein,
showed that this isoform, almost undetectable in quiescent CD4þ
T lymphocytes, increases with the time of culture and activation of
CD4þ T lymphocytes (Fig. 1D). Therefore CXCR4 protein expression
pathway, inversely correlated to its mRNA expression (Fig. 1C),
indicates a posttranscriptional control of CXCR4 mRNA by miR-
146a in these cells.
We also examined the expression and regulation of another
target of miR-146a, TRAF6, in activated CD4þ T lymphocytes. As
observed for CXCR4, TRAF6 mRNA level decreases during the ﬁrst
hours of activation of CD4þ T cells, then remains at a lower level
later in culture (from 16 to 24 hours), decreasing slightly at 48
hours (Fig. 1E), whereas the decrease of miR-146a (Fig. 1B) may
unblock TRAF6 mRNA translation and then increase TRAF6 protein
expression level in these cells (Fig. 1F).
Altogether, our data suggest that the regulation of CXCR4, but
also of TRAF6, protein expression level in resting and activated
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CD4þ T lymphocytes is under the posttranscriptional control of
miR-146a, whereby an increased PLZF level suppresses transcrip-
tion of miR-146a, hence activating CXCR4 and TRAF6 mRNA
translation.
HIV-1 infection have no effect on PLZF, miR-146a, and CXCR4
expression and regulation in human CD4þ T lymphocytes
To study whether HIV-1 entry and replication into CD4þ T
lymphocytes may have an impact on the cascade pathway resulting
in the control of CXCR4 protein level in these cells, we analyzed
PLZF, miR-146a and CXCR4 expression and regulation in HIV-1
infected CD4þ T lymphocytes.
Following 6 hours of activation, cells were infected by using
NL4-3 HIV-1 virus (Adachi et al., 1986), and harvested at 16, 24 and
48 hours post-infection for analysis.
Similarly to what we observed in CD4þ T lymphocytes (Fig. 1),
western blot analysis showed that PLZF protein expression is
activated (Fig. 2A), whereas miR-146a expression level is decreased
in PHA activated CD4þ(HIV-1) T lymphocytes (Fig. 2B), as compared
to quiescent CD4þ T lymphocytes (0, Fig. 2B) and activated CD4þ T
lymphocytes of control (Fig. 1B).
Real time PCR analysis showed that CXCR4 mRNA expression level
decreases in activated CD4þ(HIV-1) cells (Fig. 2C), whereas the
45 kDa isoform of CXCR4 protein increases in these cells from 16 to
48 hours of culture, as also found in uninfected CD4þ T lymphocytes
Fig. 1. PLZF, miR-146a and its targets, CXCR4 and TRAF6, are expressed and regulated in CD4þ T lymphocytes. (A) Western blot analysis of PLZF protein expression in
quiescent and PHA-activated CD4þ T lymphocytes. Hel cell line is a positive cell line for PLZF expression. (B) Real time PCR analysis of miR-146a expression in quiescent and
PHA-activated CD4þ T lymphocytes. Jurkat and U937 cells are, respectively, negative and positive control of miR-146a expression. (C) qRT-PCR analysis of CXCR4 mRNA
expression in quiescent (0) CD4þ T lymphocytes and in PHA-activated CD4þ T lymphocytes, maintained in culture for 48 hours and collected at different times. Jurkat and
U937 cells are shown as two positive controls for CXCR4 mRNA expression. (D) Western blot analysis of the 45 kDa CXCR4 protein isoform expression in quiescent and PHA-
activated CD4þ T lymphocytes maintained in culture. Jurkat cell line is a positive control expressing the 45 kDa isoform of CXCR4 protein (E) qRT-PCR analysis of TRAF6
mRNA expression in quiescent (0) and PHA-activated CD4þ T lymphocytes. U937 cell line is shown as a positive control of TRAF6 expression. (F) Western blot analysis of
TRAF6 protein expression in quiescent and PHA-activated CD4þ T lymphocytes. (A, D, F) Actin is an internal control of total protein extracts; one representative experiment
of three is shown. (B, C, E) AU is for arbitrary units; Mean7SEM values from three independent experiments are shown. nn, nnn: po0.01, po0.001, respectively. (B) miR-146a
expression levels were normalized to U6 expression levels. (C, E) CXCR4 and TRAF6 mRNAs levels were normalized to GAPDH levels.
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(Fig. 1D). Western blot analysis of p24 viral protein was also
performed to control HIV-1 infection of PHA activated CD4þ
(HIV-1) T lymphocytes (Fig. 2D).
Furthermore, HIV-1 infection seems without signiﬁcant effect
on TRAF6 mRNA and protein expression and regulation in CD4þ
(HIV-1) T lymphocytes (Fig. 2E and F), as the increase of TRAF6
protein expression from resting to PHA activated CD4þ T cells
(Fig. 2F) is probably due to the decrease of miR-146a level observed
in PHA activated CD4þ(HIV-1) T lymphocytes (Fig. 2B), whereas
TRAF6 mRNA expression is quite constant in the same cells (Fig. 2E).
To exclude that the HIV-negative population can mask any changes
in infected sub-population,we have replicated the experiments and
performed real time PCR assays by using RNA from infected and
uninfected cells puriﬁed with a monoclonal antibody anti-gp120 (mAb
4G10 from NIH AIDS Research and Reference Program) and separated
with anti-mouse magnetic beads and gp120 negative cells. Our results
Fig. 2. HIV-1 infection of activated CD4þ T lymphocytes does not modify PLZF, miR-146a, CXCR4 and TRAF6 expression patterns. (A) Western blot analysis of PLZF protein
expression in PHA-activated and infected CD4þ(HIV-1) T lymphocytes maintained in culture from 16 to 48 hours, as compared to quiescent (0) CD4þ control T lymphocytes.
(B) Real time PCR analysis of miR-146a expression in PHA-activated- (from 0 to 3 hours) and HIV-1-infected- (arrow) CD4þ T lymphocytes, maintained in culture for 48
hours, as compared to quiescent (0) CD4þ T lymphocytes. Jurkat and U937 cells are, respectively, negative and positive control for miR-146a expression. (C) qRT-PCR analysis
of CXCR4 mRNA expression in CD4þ(HIV-1) T lymphocytes, PHA-activated (from 0 to 3 hours) ﬁrst, then HIV-1 infected (arrow) and maintained in culture for 48 hours, as
compared to quiescent (0) CD4þ T lymphocytes. Jurkat and U937 cells are positive controls for CXCR4 mRNA expression. (D) Western blot analysis of the 45 kDa CXCR4
protein isoform expression in PHA-activated (PHA 16 and 48 hours) and HIV-1-infected (HIV-1) CD4þ T lymphocytes, as compared to 16 and 48 h PHA-activated CD4þ
control (C) T lymphocytes. Jurkat cells are shown as positive control of 45 kDa isoform of CXCR4 protein. Western blot analysis of viral p24 protein expression is shown as a
control of HIV-1 infection of PHA-activated CD4þ(HIV-1) T lymphocytes. (E) qRT-PCR analysis of TRAF6 mRNA expression in CD4þ(HIV-1) T lymphocytes, PHA-activated
(from 0 to 3 h) ﬁrst, then HIV-1 infected (arrow) and maintained in culture for 48 h, as compared to quiescent (0) CD4þ T lymphocytes. U937 cells are positive control for
TRAF6 mRNA expression. (F) Western blot analysis of TRAF6 protein expression in PHA-activated and infected CD4þ(HIV-1) T lymphocytes maintained in culture from 16 to
48 h, as compared to quiescent (0) CD4þ control T lymphocytes. (B, C, E) Mean7SEM values from three independent experiments are shown. nn, nnn: po0.01, po0.001,
respectively. (A, D, F) Actin is shown as an internal control of total protein extracts; one representative experiment of three is shown.
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conﬁrmed that miR-146a, CXCR4 and TRAF-6 mRNAs expression are
not modiﬁed between infected and uninfected cells (data not shown).
Overall, our data show that HIV-1 entry and replication into
activated CD4þ T lymphocytes is without any signiﬁcant effect on
PLZF, miR-146a and, consequently, on CXCR4 or TRAF6 expression
and regulation in these cells.
AMD3100 that impairs HIV-1 entry via CXCR4 into CD4þ T
lymphocytes induces miR-146a expression in both CD4þ and
CD4þ(HIV-1) T lymphocytes
AMD3100, as an inhibitor of CXCR4, is able to block HIV-1 entry
via CXCR4 into CD4þ T lymphocytes.
We have previously demonstrated that AMD3100 treatment of
U937 cells increases miR-146a expression, thus decreasing CXCR4
protein expression level in these cells (Spinello et al., 2011). Here
we analyzed whether AMD3100 may have a similar effect in CD4þ
T lymphocytes, HIV-1 infected or not (Fig. 3).
First, we evaluated CXCR4 membrane protein expression level in
PHA activated CD4þ T lymphocytes maintained in culture for 48
hours in presence, or not, of AMD3100 (Fig. 3A). Flow cytometry
analysis showed that CXCR4 membrane protein expression is
upregulated on CD4þ T lymphocytes after 48 hours of activation,
as compared to resting (d0) CD4þ T lymphocytes, while the
blockade of CXCR4 by AMD3100 treatment (Hatse et al., 2003)
decreases CXCR4 membrane protein level detected by ﬂow cyto-
metry analysis (Fig. 3A).
Next, we infected activated CD4þ T lymphocytes, treated or not
with AMD3100, with NL4-3 HIV-1 strain (Adachi et al.,1986) and
analyzed these cells at 24- and 48-h postinfection by ﬂow cytome-
try to examine the infection efﬁciencies (Fig. 3B). Levels of intracy-
toplasmic HIV-CAp24 expression increase with the time of culture,
as indicated by the number of PE-p24-CD4þ positive cells detected
by ﬂow cytometry analysis from 8.9% to 25%. Moreover, AMD3100
treatment inhibits HIV-1 entry via CXCR4 in CD4þ T lymphocytes,
as shown by the low level of PE-p24-CD4þ positive cells detected
by ﬂow cytometry analysis in these cultures (Fig. 3B).
Then, we analyzed miR-146a expression in activated CD4þ and
CD4þ(HIV-1) T lymphocytes, AMD3100 treated or not, harvested
following 48 hours of culture.
We found that AMD3100 treatment of CD4þ and CD4þ(HIV-1)
T lymphocytes increases miR-146a expression (Fig. 3C) that, in
turn, decreases protein expression levels of both 45 kDa CXCR4
protein isoform (Fig. 3D) and TRAF6 (Fig. 3E), without signiﬁcant
modulation of CXCR4 and TRAF6 mRNAs expression level (data not
shown). However, we did not detect any signiﬁcant effect of
AMD3100 treatment on PLZF protein expression in AMD3100
treated -CD4þ and -CD4þ(HIV-1) cells (not shown), as compared
to untreated cells (Figs. 1A and 2A).
Altogether, our data showed that other that an inhibitor of
CXCR4 that blocks HIV-1 entry into CD4þ T lymphocytes, AMD3100
treatment can also be used to increase miR-146a expression level
that controls two pathways, the one involving CXCR4 and HIV-1
entry in CD4þ T lymphocytes, and the other involving TRAF6 to
further investigate in HIV-1 infection of CD4þ T lymphocytes.
miR-146a enforced expression or treatment with AMD3100, decreases
CXCR4 protein level and inhibits HIV-1 infection of U937(miR-146a)
cells
We have previously demonstrated that miR-146a decreases
CXCR4 protein expression level in U937(miR-146a) cells, as com-
pared to CXCR4 expressing U937(E) control cells (Spinello et al.,
2011). Here, we used these cell lines to verify whether miR-146a
overexpression in U937(miR-146a) cells may inhibit HIV-1 infec-
tion of these cells.
We used the HIV-1 chronically infected U937 cell line (U937HIV-1)
(Muratori et al., 2007) to infect U937(E) control cells, as compared to
U937(miR-146a) cells.
By co-cultivating U937HIV-1 cells with U937(E), as compared to
U937(miR-146a) cells, we monitored HIV-1 infection at different
times of co-cultures (6, 24 and 48 hours) analyzing intracellular
p24 viral protein and green ﬂuorescence protein (GFP) expression
by ﬂow cytometry (FC) analysis (Fig. 4).
FC analysis showed U937HIV-1 cells as PE labeled-p24 positive
cells, U937(miR-146a) and U937(E) uninfected cells as GFP positive
cells, whereas U937(E) and U937(miR-146a) infected cells are PE
labeled-p24/ GFP double positive cells (Fig. 4).
In co-cultures of U937(E)/U937HIV-1 cells, we observed an
increase of the percentage of PE-p24/GFP double positive cells from
15.6% to 33% corresponding to the increase of U937(E) infected cells
in co-culture (Fig. 4A), whereas the percentage of PE-p24/GFP
double positive cells detected in co-cultures of U937(miR-146a)/
U937HIV-1 cells is lower (Fig. 4B).
After 48 hours of co-culture, 15% U937(miR-146a) infected cells
are detected by FC analysis (Fig. 4B), whereas 33% of U937
(E) infected cells are found (Fig. 4A), indicating that U937(miR-
146a) cells are less susceptible to HIV-1 infection, as compared to
U937(E) cells.
Then we showed that a treatment of 48 hours with AMD3100
inhibits HIV-1 infection of CXCR4 expressing U937(E) cells, as
indicated by the low percentage (5,1%) of PE-p24/GFP double positive
cells detected in co-cultures (Fig. 4A, 48 hþAMD3100), as compared
to the high percentage (34%) of PE-p24/GFP double positive cells
detected in untreated U937(E)/U937HIV-1 co-cultures (Fig. 4A, 48 h –
AMD3100). Because U937(miR-146a) cells are negative for CXCR4
membrane expression, AMD3100 treatment has no signiﬁcant effect
on HIV-1 infection of these cells (not shown) that are quite resistant
to HIV-1 entry (Fig. 4B).
Overall, these data showed the ability of HIV-1 virus produced
by U937HIV-1 cells to infect U937(E), but not U937(miR-146a) cells,
thus indicating that HIV-1 entry occurs via CXCR4 coreceptor in
these cells.
Altogether, our data demonstrated that miR-146a enforced
expression and AMD3100, acting through different mechanism to
down-modulate CXCR4 protein levels (Spinello et al., 2011), inhibits
HIV-1 entry into U937(miR-146a) and U937(E) cells, as also
observed in CD4þ T lymphocytes (Fig. 3).
Knockdown of PLZF increases miR-146a that, in turn, decreases
CXCR4 protein level and impairs HIV-1 infection via CXCR4 of CD4þ T
lymphocytes
We investigated whether PLZF, as a repressor of miR-146a
identiﬁed in Mk cells (Labbaye et al., 2008), may control CXCR4
protein expression in CD4þ T lymphocytes and play a role in HIV-1
infection of these cells.
First, we transfected activated CD4þ cells with siRNAs that
speciﬁcally blocked PLZF expression (siR-PLZF) (Labbaye et al.,
2008), or non-targeting control siRNA (siR-C), and examined PLZF,
miR-146a and CXCR4 protein expression in CD4þ(siR-PLZF) cells,
as compared to control CD4þ(siR-C) cells.
Our data show that silencing of PLZF mRNA that induces a
decrease of PLZF protein expression level (Fig. 5A, upper panel),
up-regulates miR-146a expression in CD4þ(siR-PLZF) cells (Fig. 5B)
that, in turn, decreases the 45 kDa CXCR4 protein isoform in these
cells, as compared to control CD4þ(siR-C) cells (Fig. 5A, middle
panel).
Next, we performed HIV-1 infection of CD4þ(siR-PLZF) cells
and CD4þ(siR-C) cells, by using NL4-3 HIV-1 virus to analyze
susceptibility of these cells to viral infection.
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Fig. 3. AMD3100 increases miR-146a expression that, in turn, decreases CXCR4 and TRAF6 protein levels, thus preventing HIV-1 entry into CD4þ T lymphocytes.
(A) Representative histograms of CD4þ T lymphocytes analyzed by ﬂow cytometry (FC) for CXCR4 membrane protein expression in resting (d0), PHA-activated (48 h) and
PHA-activated-AMD3100 treated (48 hþAMD3100) CD4þ T lymphocytes. The relative percentage of CXCR4 membrane protein detected is indicated as compare to IgG-PE
control CD4þ cells. One representative experiment of three is shown. (B) FC analysis for the expression of HIV-1 CAp24 in activated CD4þ T lymphocytes 24 and 48 h after
challenge. The cells, treated or not, with AMD3100 and infected with 150 ng/105 cells of HIV-1 NL4-3 strain, are labeled with a PE-conjugated anti Cap24 HIV-1 mAb and
analyzed by FC analysis. In the histograms, dotted line and solid gray histogram represent respectively, AMD3100 treated cells and not. The scale of Y axis is linear and
represents events as % of max. One representative experiment of three is shown. (C) qRT-PCR of miR-146a expression shows that AMD3100 upregulates miR-146a expression
level in, both, CD4þ T lymphocytes and infected CD4þ(HIV-1) T lymphocytes maintained in culture 48 hours, as compared to untreated cells (-AMD3100). Mean7SEM
values from three independent experiments are shown. nn, nnn: po0.01, po0.001, respectively. Jurkat and U937 cells are respectively used as negative and positive control of
miR-146a expression. (D) Western blot analysis of the 45 kDa CXCR4 isoform expression in PHA (48 h) activated -CD4þ and infected -CD4þ(HIV-1) T lymphocytes, AMD3100
treated (þ) or not (). (E) Western blot analysis of TRAF6 protein expression in PHA (48 h) activated -CD4þ and -CD4þ(HIV-1) T cells, AMD3100 treated (þ) or not (). C, is
U937 cells used as a TRAF6 expressing positive control. (D, E) Actin is shown as an internal control of total protein extracts; one representative experiment of three is shown.
Fig. 4. MiR-146a enforced expression and AMD3100 treatment, that decrease CXCR4 protein level through different mechanisms, are able to prevent HIV-1 entry into U937
(miR-146a) and U937(E) cells, respectively. (A, B) The infection efﬁciency is evaluated by estimating the percentage of GFP positive cells that are also p24 positive by ﬂow
cytometry (FC) analysis. (A) U937(E) -GFP positive cells, maintained from 6 to 48 hours in co-culture with U937HIV-1 cells, show an increase, of double PE-p24-/ GFP-labeled
U937(E) cells. AMD3100 treatment inhibits HIV-1 infection of CXCR4-expressing U937(E) cells, as compared to non-treated co-cultures, as shown by FC analysis of HIV-1
CAp24 viral p24 (PE-p24) and GFP protein expression in U937(E) -GFP positive cells, treated (þAMD3100), or not (-AMD3100), with AMD3100 and maintained 48 hours in
co-culture with U937HIV-1 cells. (B) U937(miR-146a)-GFP positive cells co-cultivated with U937HIV-1 cells show a percentage of double PE-p24-/GFP- labeled U937(miR-146a)
cells that indicates a lower infection, as compared to infection of U937(E) cells. The percentages of events for each quadrant are reported. The circled numbers represent the
percentage of the GFP positive cells that are also p24 positive. One representative experiment of three is shown.
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CD4þ(siR-PLZF) and CD4þ(siR-C) transfected cells are maintained
in cultured for 24 hours and then infected with NL4-3 HIV-1. ELISA
assay for intracellular viral p24 protein expression performed 1 and
2 days after HIV-1 infection shows about a 30% of inhibition of HIV-1
infection in CD4þ(siR-PLZF) cells, as compared to CD4þ(siR-C) cells
(Fig. 5C), thus indicating that the decrease of CXCR4 protein level
found in CD4þ(siR-PLZF) cells impairs HIV-1 entry into these cells, as
compared to HIV-1 entry into CD4þ(siR-C) cells.
Then, we performed supplementary infection experiments by
using a VSV-G pseudotyped HIV-1 NL4-3 strain that enters cells
bypassing CXCR4 receptor. We infected both CD4þ(siR-PLZF) and
CD4þ(siR-C) transfected cells with 150 ng/105 of virus and col-
lected 48 h thereafter. FC analysis for the expression of p24 shows
there is no effect of the siRNA-PLZF on infection (Fig. 5D).
Altogether, our results show that the miR-146a/CXCR4 pathway
is controlled by the PLZF suppressor in CD4þ cells and may be
used to inhibit HIV-1 entry via CXCR4 into these cells.
Discussion
CXCR4/SDF-1α interactions are central to hematopoiesis, immune
responsiveness and angiogenesis (Campbell et al., 2001; Busillo and
Benovic; 2007). Implicated in a variety of pathological conditions,
including inﬂammation and the metastasis of a variety of cancers
(Ratajczak et al; 2006; Burger and Kipps, 2006), CXCR4 provides a
receptor binding complex for the HIV envelope glycoprotein (gp120),
which facilitates HIV-1 cell fusion and viral entry by CXCR4 utilizing
X4 strains of HIV-1 (Wilen et al., 2012).
In this study, we showed that activation of CD4þ T lymphocytes
increases CXCR4 protein level while miR-146a decreases, unblocking
CXCR4 mRNA translation. This effect results in an increase expression
of the 45 kDa CXCR4 protein isoform that may support the turn-over
of CXCR4 protein surface expression, thus enhancing the suscept-
ibility for HIV-1 entry via CXCR4 into CD4þ T lymphocytes.
Because TRAF6 is one component of the IFN signaling pathway
that controls viral replication (Sirois et al., 2011; Khan et al., 2013),
but also a target of miR-146a in immune cells (Taganov et al., 2006;
Boldin et al., 2011), we analyzed TRAF6 expression at both mRNA
and protein level in resting and activated CD4þ T lymphocytes, to
examine miR-146a activity in these cells. Our data are signiﬁcant of
a posttranscriptional control of TRAF6 mRNA translation by miR-
146a targeting, as the decrease of miR-146a results in an increase of
TRAF6 protein level during activation of CD4þ T lymphocytes,
independently of HIV-1 infection, as also observed for CXCR4 in
these cells.
Fig. 5. PLZF silencing increases miR-146a expression that in turn, decreases CXCR4 protein level, and impairs HIV-1 infection of CD4þ T lymphocytes. (A) Western blot
analysis shows that inhibition of PLZF by siRNA-PLZF treatment of CD4þ T lymphocytes (siR-PLZF, upper panel), also decreases the 45 kDa CXCR4 isoform level in these cells
(siR-PLZF, middle panel), as compared to siRNA control-transfected CD4þ(siR-C) T cells. Actin is shown as an internal control of total protein extracts. One representative
experiment of three is shown. (B) qRT-PCR shows that PLZF silencing in activated CD4þ T lymphocytes increases miR-146a expression in CD4þ(siR-PLZF) T cells, as compared
to CD4þ(siR-C) T lymphocytes. Mean7SEM values from three independent experiments are shown. n: po0.05. (C) CD4þ(siR-PLZF) and CD4þ(siR-C) T lymphocytes infected
with NL4-3 HIV-1 are analyzed by ELISA assay for intracellular HIV-1 CA p24 expression. (D) FC analysis of HIV-1 CAp24 viral p24 (PE-p24) on CD4þ(siR-PLZF) and CD4þ(siR-
C) T lymphocytes infected with 150 ng/105 cells of VSV-G NL4-3 HIV-1, and maintained in culture for 48h. p24 expression level is the same in both infected CD4þ(siR-PLZF)
(VSV-G/HIV) and CD4þ(siR-C) (VSV-G/HIV) T lymphocytes. (C, D) The data shown are representative of three independent experiments with similar results.
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miR-146a expression is downregulated by the activation of
CD4þ T lymphocytes, without any signiﬁcant alteration of expres-
sion during HIV-1 replication in HIV-1 infected CD4þ T lympho-
cytes, thus increasing both CXCR4 and TRAF6 protein expression
level in these cells. Upregulation of CXCR4 and TRAF6, through
different pathways, promotes HIV-1 entry and replication in acti-
vated CD4þ T lymphocytes. During viral infection, the expression of
miRNAs that target viral sequences or host genes that inﬂuence the
course of viral replication and pathogenesis may be altered (Houzet
and Jeang, 2011; Klase et al., 2012). Here we found that miR-146a is
expressed in human primary resting CD4þ T lymphocytes, down-
regulated during their activation, but its inﬂuence on HIV-1
replication should be further investigated.
Altogether, our ﬁndings indicate that miR-146a is implicated in
two regulatory pathways during activation of CD4þ T lymphocytes,
the one that involved CXCR4 and HIV-1 entry into CD4þ cells, the
other involving TRAF6 possibly correlated with HIV-1 replication in
CD4þ cells, indicating the possibility for miR-146a to be used as a
tool to knockdown its targets and control HIV-1 entry/replication in
human CD4þ T lymphocytes.
Interestingly, as we previously downmodulated CXCR4 at both
surface and intracytoplasmic levels by enforced miR-146a expression
in monocytic leukemic cells (Spinello et al., 2011), here we showed
that miR-146a overexpression prevents HIV-1 entry into U937(miR-
146a) cells, as compared to the CXCR4 expressing U937(E) cells of
control. TRAF6 protein is also downmodulated in U937(miR-146a)
cells (our unpublished data) and may be involved in resistance to
HIV-1 infection that we observed with these cells. Therefore, as a
recent study performed on human macrophages has shown that the
knockdown of TRAF6, but also TRAF2 and 5, results in decreased NF-kB
activation and reduces HIV-1 replication in monocyte-derived macro-
phages (Khan et al., 2013), understanding the role of the miR-146a/
TRAF6 axis in HIV-1 infection of Mo leukemic cells and CD4þ T
lymphocytes, in the context of the complex TRAF signaling, requires
future dedicated studies.
The critical role of CXCR4 in HIV-1 infection, together with the
cell types expressing CXCR4, encouraged the design of new anti-
HIV drugs aimed at blocking CXCR4 function (Steen et al., 2009;
Murakami and Yamamoto, 2010; Choi et al., 2012a, 2012b). In fact,
whether the use of speciﬁc inhibitors of CCR5 has been approved
for clinical use (Boesecke and Pett, 2012), the necessity to ﬁrst
identify which co-receptor is used by the strains infecting each
patient has emerged, in part due to the risk on selecting the more
pathogenic strains that use the CXCR4 co-receptor. Viruses that
use CXCR4 (X4) or both, CCR5 (R5) and CXCR4, rare in early
disease, emerge over time and are associated with disease pro-
gression, as the prevalence of X4 variants increases with decreas-
ing CD4þ T cell count observed in patients with chronic disease
(Fiser et al., 2010; Duquenne et al., 2014).
Whether preliminary studies with AMD3100, used as an anti-
retroviral agent antagonist of CXCR4, have not been satisfactory
(Hendrix et al., 2000, 2004), exposure of CD4þ T lymphocytes to
this agent determines the rapid and massive downmodulation of
surface CXCR4 due to receptor internalization, while the total
receptor expression remains virtually unmodiﬁed. In our study,
we showed that prolonged exposure of activated CD4þ T lympho-
cytes to AMD3100 induces a decrease of total CXCR4, a phenom-
enon possibly related to intracellular receptor degradation and also
to reduced receptor translation, but also associated to an increased
expression of miR-146a in CD4þ T lymphocytes, these effects being
associated to an inhibition of HIV-1 infection of these cells.
Resting CD4þ T cells and monocytes are non-permissive for HIV-1
infection. Also, the resting state and the cause behind viral restriction
in resting cells are currently under discussion (Chiang and Rice,
2012). It is of interest to note that miR-146a is highly expressed in
resting CD4þ T lymphocytes and inhibits the expression of both
CXCR4 (i.e., the 45 kDa isoform) and TRAF6 cellular proteins that are
not viral co-factors, without excluding some other target genes of
miR-146a directly involved in viral replication to identify. However, if
miR-146a is, currently, not an anti-HIV miRNAs (Chiang and Rice,
2012), following activation miR-146a exhibits decreased expression,
while CXCR4 and TRAF6 are up-regulated contributing to a favorable
milieu for virus entry and/or replication.
Here, we found that the transcription factor PLZF is a repressor
of miR-146a expression in activated CD4þ T lymphocytes. Unde-
tectable in resting CD4þ T lymphocytes, following activation, PLZF
increases and downregulates miR-146a, thus increasing CXCR4
protein level in activated CD4þ T lymphocytes. PLZF knockdown
induced the opposite effects and impaired HIV-1 infection of
these cells.
Whether PLZF expression was found to be restricted to invar-
iant NKT (iNKT) cells, a subgroup of NK T-lymphocyte (NKT) cells
with distinctive properties, (Savage et al., 2008) and more recently,
PLZF was shown to direct the developmental acquisition of the
innate effector program of NK T cells (Michael et al., 2014), in
human the role of PLZF should be reconsidered in the adaptive
immune response and in the pathogenesis of the HIV-1 infection.
Altogether, we identify a cascade pathway, in which PLZF sup-
presses miR-146a transcription and thereby activates CXCR4 transla-
tion during activation of CD4þ cells, that may be used to inhibit
HIV-1 infection. Our ﬁndings also suggest that an optimal therapeutic
effect potentially deriving from inhibition of the CXCR4/SDF-1α axis
may require a combined effect both at the level of CXCR4 content
(i.e., decreasing it by miR-146a overexpression) and of SDF-1α/CXCR4
interaction (i.e., inhibiting this interaction using AMD3100 or similar
agents). miR-146a overexpression may be achieved by using the
miRNA mimic technology, an innovative approach for gene silencing
to use in miRNA-based cancer therapy (Yeung and Jeang, 2011), but
also by blocking the active recruitment of histone deacetylases
(HDACs) with which PLZF interacts to achieve its inhibitory effect
through chromatin remodeling (Suliman et al., 2012). In this context,
it is of interest to note that a study has previously reported the
synergistic antileukemic activity of AMD3100 and a histone deace-
tylase inhibitor that markedly upmodulates miR-146a levels and
decreases CXCR4 level (Mandawat et al, 2010).
Materials and methods
Cell cultures
Human adult peripheral blood mononuclear cells (PBMCs) were
obtained from healthy donors after written informed consent and
processed under approval of the ethical committee of Istituto Super-
iore di Sanità (ISS), in accordance with the Declaration of Helsinki
and prepared by ﬁcoll (Ficoll-Paque GE Healthcare) gradient
centrifugation.
Primary CD4þ T lymphocytes were isolated untouched from
PBMCs by negative selection using magnetic beads (CD4þ T cell
isolation kit II, Miltenyi Biotech, Germany) following the manufac-
turer's recommendations. The purity of recovered cell populations
was assayed by FACS analysis by means of PE-conjugated anti-CD4
mAb (BD Biosciences, Mountain View, CA) labeling. Cell prepara-
tions staining below 95% positive for CD4 were discarded.
For activation, primary CD4þ T lymphocytes were treated with
phytohemagglutinin (PHA) 5 mg/ml, (Sigma-Aldrich Co., St. Louis,
MO) for 24 h at 37 1C and cultured in interleukin (IL-2) containing
medium (50 U/ml, R&D Systems, Minneapolis, MN). Non-activated T
cells were kept in RPMI 1640 (Life Technologies, Italy) supplemen-
ted with 10% FBS (Gibco, Carlsbad, CA, USA) without exogenous
cytokines. Cultures of CD4þ cells were maintained few days, after
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addition (PHA) for activation of these cells for the duration of
experimentation (Gowda et al., 1989a, 1989b).
Co-cultivations were typically set up in 1ml of RPMI-10% Fetal
Bovine Serum in 12-well plates by seeding 5105 target cells with
106 donor cells.
U937 cells, an human cell line displaying many monocyte/
macrophage features, Jurkat cells, an immortalized line of human T
lymphocyte cells and HEL cells, a human erythroleukemic cell line
were cultured using standard methods.
U937HIV-1 is a cell line derived from U937 cells recovered upon
chronic infection with the human T-lymphotropic virus IIIB HIV-1
isolated, as previously described (Muratori et al., 2007).
U937(E) and U937(miR-146a) cell lines were previously prepared
upon infection of target U937 cells respectively with, an empty pCDH/
Green Fluorescent Protein expression lentivector (pCDH/GFP-E) used
for internal control and with the human miR-146a precursor cloned
into the pCDH/GFP-miR-146a expression lentivector (PMIRH146aPA-1,
System Biosciences, Mountain View, CA, USA) (Spinello et al, 2011).
U937HIV-1, U937(E) and U937(miR-146a) cells are grown in RPMI
1640 culture medium supplemented with 10% heat-inactivated FBS.
GFP expression was evaluated by ﬂow cytometry analysis. Their
co-cultivations were also set up in 1 ml of RPMI-10% FBS in 12-well
plates by seeding 5105 target cells with 106 donor cells.
HIV-1 preparation and infection
Supernatants from transiently transfected 293T cells were used as
the source of both NL4-3 HIV-1 and NL4-3 HIV-1 pseudotyped with
the envelope glycoprotein of the vesicular stomatitis virus (VSV-G) as
described (Adachi et al., 1986). For the infection experiments of CD4þ
cells, supernatants were concentrated by ultracentrifugation and
titrated by measuring the HIV-1 CAp24 content by quantitative
enzyme-linked immunosorbent assays (ELISA, Innogenetics, Gent,
Belgium) and by reverse transcriptase assays (Olivetta et al., 2000).
CD4þ cells were infected by spinoculation at 400 g for 30 min at
room temperature using 150 ng/105 cells of viruses. Virus adsorption
was prolonged for an additional 2 h at 37 1C, and ﬁnally, the cells
were washed and reefed with the complete medium.
Flow cytometry analysis (FC)
2104 cells aliquots were labeled on the membrane using the
phycoerythrin (PE)-conjugated anti-CXCR4 monoclonal antibody
(clone 12G5, BD/Pharmingen, SanDiego,CA, USA) or a control PE-
conjugated mAb of the same isotype (Spinello et al., 2011). All
experiments were performed with the same batch of anti-CXCR4
conjugated antibody.
The percentages of cells expressing intracytoplasmic HIV-1 Gag-
related products were evaluated by FC analysis after permeabiliza-
tion with Cytoﬁx/Cytoperm solutions (BD biosciences) for 20 min at
4 1C and labeling with 1/100 dilution of KC57-RD1 phycoerythrin
(PE)-conjugated anti HIV-1 Gag CAp24 KC-57 (PE-p24) MAb (Coul-
ter Corp., Hialeah, FL, USA). The % of positive cells were calculated
comparing samples stained with matched isotype used as control of
non-speciﬁc ﬂuorescence signals.
Dead cells were excluded by Sytox Blue staining (1 mM, Mole-
cular Probes, Carlsband, CA, USA).
Stained cells were analyzed by using a BD FACSAria (BD
Biosciences), equipped with three lasers (488 nm, 635 nm and
407 nm), and the results were analyzed by BD FACSDiva Software
version 6.1.3 (BD Biosciences) or FlowJo Software version 7.6.1 (Tree
Star, Inc., Ashland, OR, USA).
Quantitative real time RT-Polymerase Chain Reaction (PCR)
Total RNAs were extracted using Trizol reagent and reverse
transcribed (RT-) by Moloney murine Leukemia virus reverse
transcriptase (Invitrogen, Carlsbad, CA, USA) with random primers.
Gene expression analysis of CXCR4 and TRAF6 mRNAs was
detected by real time quantitative RT-PCR analysis (qRT-PCR) using
commercial ready-to-use primers/probe mixes (Applied Biosystems,
Foster City, CA, USA) for CXCR4 (Hs00607978_s1), TRAF6
(Hs00270336) and normalized with GAPDH (assay 20X, 4328317E),
according to the manufacturer's procedure and by using TaqMan
technology and an ABI Prism 7900 Sequence Detector (Applied
Biosystems, Foster City, CA, USA) (Spinello et al., 2011).
Real time PCR for miR-146a was performed using TaqManHMiRNA
Assays protocol (assay ID 000468, Applied Biosystems, Foster City, CA,
USA). Reverse transcriptase reaction was performed using 50 ng of
total RNA and 50 nM miRNA speciﬁc stemloop miR-146a-RT primers.
Real-time quantitative RT-PCR was performed using standard protocol
(Spinello et al., 2011). All reactions were run in duplicate. Normal-
ization was performed by using U6 snRNA primer kit (ID 001973,
Applied Biosystems). Relative expression was calculated with relative
standard curves for both the miRNA of interest and the endogenous
control, as previously described (Spinello et al., 2011).
Western blotting
Total protein extract and Western blot analysis on 7, 5% SDS-PAGE
gel were performed according standard procedures for CXCR4, PLZF,
TRAF6 and p24 proteins expression, by using polyclonal antibodies
(pAb) anti-CXCR4 and anti-PLZF (respectively, ab2074 and ab39354,
Abcam, Cambridge, UK) and monoclonal antibodies (mAb) anti-
TRAF6 (D-10) (sc-8409, Santa Cruz Biotechnology, ) and anti-HIV
p24 (ab9071, Abcam, Cambridge, UK). As an internal control of total
proteins, we used the anti-Actin mAb (clone JLA20, Calbiochem, San
Diego, CA, USA).
AMD3100 drug treatment cells and HIV-1 infection
CD4þ T lymphocytes were ﬁrst activated few hours by addition
of PHA in culture and then treated, or not, with (1 mM) AMD3100
(Sigma-Aldric, St Louis, MO) 16 hours. Infection of AMD3100
treated CD4þ T lymphocytes was then performed as described
above and as compared to untreated HIV-1 infected or not CD4þ T
lymphocytes. FC analysis of viral p24 expression was performed
after 24 and 48 hours of co-culture with, or without, AMD3100.
U937(miR-146a) and U937(E) cells (5104 cells/ml) were treated
or not few hours (3 to 6 hours) with AMD3100 (10 mM) (Sigma-Aldric,
St Louis, MO) as previously described (Spinello et al., 2011), before to
perform infection in co-culture experiments with U937HIV-1 cells,
maintained for 12 to 24 hours, always in presence of AMD3100.
Cellular populations present in co-cultures were then analyzed by FC
for GFP, p24 and double GFP/p24 expression.
Silencing of PLZF expression by siRNAs transfection
Two double-stranded PLZF siRNA (siR-PLZF) sequences
(NM_001018011) and the control siRNA sequence (siR-C) with no
homology to the human genome (Dharmacon), were previously
used to knockdown PLZF mRNA and protein expression (Labbaye
et al., 2008). Activated CD4þ T lymphocytes (5105 cells/ml) were
transfected with 90 nM siR-PLZF or siR-C by using Lipofectamine
3000 according to the manufacturer's instructions and as pre-
viously described (Labbaye et al., 2008). After 24 hours, trans-
fected CD4þ(siR-PLZF) and CD4þ(siR-C) T lymphocytes were
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infected or not by spinoculation with 150 ng CAp24 equivalent of
HIV-1 NL4-3 strain/105 cells and maintained in culture 24 to 48
hours and then collected to analyze PLZF and CXCR4 protein
expression by Western blotting and miR-146a by real-time PCR.
At the same time infection was carried out on CD8þ T cell puriﬁed
from the same donor, in order to normalize the amount of virus
entry. Infection of CD4þ(siR-PLZF), CD4þ(siR-C) and CD8þ T cells
was then evaluated by intracellular assay of p24 viral protein
expression in these cells.
Viral intracellular p24 assay
Puriﬁed CD4þ and CD8þ T cells (105 cells/well in 96-well plates)
were infected or not by spinoculation at 400 g for 30' at room
temperature using 150 ng CAp24 equivalent of NL4-3 HIV-1/105
cells, followed by virus adsorption for 3 hours at 37 1C and addition
of complete medium. At different times, cells were washed and
treated with trypsin for 5 min to remove uninternalized viruses
from their surface. Then, the cells were disrupted in lysis buffer
(PBS, 0.05% Tween 20, 2.5% Triton X-100) and infection efﬁciency
was evaluated 24 and 48 h after infection by intracellular p24 ELISA.
The experiment was performed in duplicate, and the amount of
intracellular p24 was normalized for number cells after background
subtraction.
Statistical analysis
Statistical signiﬁcance of differences observed between differ-
ent experimental groups was determined using a Student's t test.
The minimal level of signiﬁcance was a P value below 0.05.
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